On Thursday, September 5th at 4pm ET, join us for a webinar featuring Dr. Dale Shepard from the Cleveland Clinic. He will explain how impactful the testing of biomarkers is in the diagnosis and treatment of desmoid tumors. He will also touch on genetic testing in relation to CTNNB1 mutations.

Register Here

Dale R. Shepard MD, PhD is the Director of the Taussig Phase I and Sarcoma programs at Cleveland Clinic. In this role, Dr. Shepard oversees the early development of the new cancer therapies including the genomic-based treatments and immunotherapies that are revolutionizing the care of patients with cancer. He sees nearly 200 sarcoma consults annually with patients from across the country including patients with desmoid tumors. As a medical oncologist and clinical researcher, he has been the principal investigator for dozens of clinical trials and has been a recipient of a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. Dr. Shepard is a thought leader for management of sarcoma, gastrointestinal and genitourinary cancers and has been a consultant for many pharmaceutical companies. He earned a PhD in Pharmacology and his MD at The Ohio State University and completed a Clinical Pharmacology fellowship at the University of Chicago.

Thank you to our DTAM Virtual Event sponsor, Recursion, for supporting this special awareness month.